What's fueling the biotech engine—2011 to 2012

@article{Aggarwal2012WhatsFT,
  title={What's fueling the biotech engine—2011 to 2012},
  author={S. Aggarwal},
  journal={Nature Biotechnology},
  year={2012},
  volume={30},
  pages={1191-1197}
}
  • S. Aggarwal
  • Published 2012
  • Medicine, Biology
  • Nature Biotechnology
  • Sales in the biologics sector show modest but healthy growth rates for the fourth consecutive year, with cancer drugs garnering the greatest revenues. As the diabetes epidemic grows and innovation of insulins continues, drug companies in that space are moving up in the ranks. 
    80 Citations

    Topics from this paper.

    What's fueling the biotech engine—2012 to 2013
    • 211
    • PDF
    Estimating the biotech sector's contribution to the US economy
    • R. Carlson
    • Medicine, Biology
    • Nature Biotechnology
    • 2016
    • 65
    A survey of breakthrough therapy designations
    • 26
    Mammalian cell cultures for biologics manufacturing.
    • 44
    • PDF
    Molecular pharming’s foot in the FDA’s door: Protalix’s trailblazing story
    • T. Mor
    • Medicine
    • Biotechnology Letters
    • 2015
    • 34
    Natural product drug delivery: A special challenge?
    • 4

    References

    SHOWING 1-10 OF 18 REFERENCES
    What's fueling the biotech engine--2010 to 2011.
    • 74
    What's fueling the biotech engine—2009–2010
    • 76
    Targeted cancer therapies
    • 145
    • PDF
    The past 200 years in diabetes.
    • K. Polonsky
    • Medicine
    • The New England journal of medicine
    • 2012
    • 224
    • PDF
    Pfizer's JAK inhibitor sails through phase 3 in rheumatoid arthritis
    • K. Garber
    • Medicine, Biology
    • Nature Biotechnology
    • 2011
    • 56
    Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.
    • 528
    • PDF
    Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.
    • 641
    • PDF
    Bevacizumab in the treatment of ovarian cancer
    • 53